In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
2025 FEB 06 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News-- Researchers detail new data in Biotechnology - Gene Therapy. According to news reporting originating in Boston ...
Pharmaceutical Technology on MSN
Eli Lilly buys Adverum in eye disease gene therapy punt
"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...
Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...
CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...
Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...
Pharmaceutical Technology on MSN
Galapagos to shutter cell and gene therapy unit
The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback